Drug Profile
Research programme: proto-oncogene protein c-met inhibitors - Bayer HealthCare Pharmaceuticals
Alternative Names: BAY 853474; MET inhibitors - Bayer HealthCare PharmaceuticalsLatest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals
- Class
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for preclinical development in Cancer in Germany (PO)
- 16 Apr 2016 BAY 853474 is still in preclinical development for Cancer in Germany
- 01 Mar 2011 Bayer Schering Pharma is now called Bayer HealthCare Pharmaceuticals